PIEZO2 Gene Arthrogryposis distal type 3 Genetic Test
At DNA Labs UAE, we offer the PIEZO2 Gene Arthrogryposis distal type 3 Genetic Test. This test is designed to identify mutations or variations in the PIEZO2 gene that may be responsible for causing Arthrogryposis distal type 3 (DA3).
Test Details
The PIEZO2 gene is associated with a condition called Arthrogryposis distal type 3 (DA3). This genetic test, also known as Next-Generation Sequencing (NGS) genetic test, is used to identify mutations or variations in the PIEZO2 gene that may be responsible for causing DA3.
Arthrogryposis refers to a group of conditions characterized by multiple joint contractures, meaning that certain joints in the body are stiff and have limited movement. DA3 specifically affects the distal joints, which are the joints farthest from the center of the body, such as those in the hands and feet.
NGS genetic testing involves sequencing the DNA of an individual to identify specific variations or mutations in genes associated with a particular condition. In the case of DA3, this test would analyze the PIEZO2 gene to identify any variations or mutations that may be responsible for the development of the condition.
The results of this genetic test can help confirm a diagnosis of DA3 and provide information about the specific genetic variant involved. This information can be valuable for understanding the underlying cause of the condition, predicting disease progression, and guiding treatment options and management strategies.
Test Components and Price
Test Name: PIEZO2 Gene Arthrogryposis distal type 3 Genetic Test
Components: NGS Technology
Price: 4400.0 AED
Sample Condition and Report Delivery
Sample Condition: Blood or Extracted DNA or One drop Blood on FTA Card
Report Delivery: 3 to 4 Weeks
Test Type and Doctor
Test Type: Osteology Dermatology Immunology Disorders
Doctor: Dermatologist
Test Department and Pre Test Information
Test Department: Genetics
Pre Test Information: Clinical History of Patient who is going for PIEZO2 Gene Arthrogryposis, distal, type 3 NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with PIEZO2 Gene Arthrogryposis, distal, type 3 NGS Genetic DNA Test gene PIEZO2.
Test Name | PIEZO2 Gene Arthrogryposis distal type 3 Genetic Test |
---|---|
Components | |
Price | 4400.0 AED |
Sample Condition | Blood or Extracted DNA or One drop Blood on FTA Card |
Report Delivery | 3 to 4 Weeks |
Method | NGS Technology |
Test type | Osteology Dermatology Immunology Disorders |
Doctor | Dermatologist |
Test Department: | Genetics |
Pre Test Information | Clinical History of Patient who is going for PIEZO2 Gene Arthrogryposis, distal, type 3 NGS Genetic DNA Test. A Genetic Counselling session to draw a pedigree chart of family members affected with PIEZO2 Gene Arthrogryposis, distal, type 3 NGS Genetic DNA Test gene PIEZO2 |
Test Details |
The PIEZO2 gene is associated with a condition called arthrogryposis, distal, type 3 (DA3). This genetic test, also known as Next-Generation Sequencing (NGS) genetic test, is used to identify mutations or variations in the PIEZO2 gene that may be responsible for causing DA3. Arthrogryposis refers to a group of conditions characterized by multiple joint contractures, meaning that certain joints in the body are stiff and have limited movement. DA3 specifically affects the distal joints, which are the joints farthest from the center of the body, such as those in the hands and feet. NGS genetic testing involves sequencing the DNA of an individual to identify specific variations or mutations in genes associated with a particular condition. In the case of DA3, this test would analyze the PIEZO2 gene to identify any variations or mutations that may be responsible for the development of the condition. The results of this genetic test can help confirm a diagnosis of DA3 and provide information about the specific genetic variant involved. This information can be valuable for understanding the underlying cause of the condition, predicting disease progression, and guiding treatment options and management strategies. |